CME; esophageal cancer; PD-1 inhibitor

Overview
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Harry H. Yoon, MD, MHS  
Enterprise Co-Leader
GI/Hepatobiliary/Pancreatic Cancer Research Program  
Enterprise Vice-Chair, GI Cancer Disease Group  
Mayo Clinic Comprehensive Cancer Center  
Rochester, MN 
Dr. Yoon has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: Amgen, Bristol Myers Squibb, CARsgen Therapeutics, Macrogenics, Merck
Consulting fees: ALX Oncology, Amgen, Astellas, AstraZeneca, BeiGene, Bristol Myers Squibb, Elevation Oncology, Macrogenics, Merck, Novartis, OncXerna, and Zymeworks
Other (Travel/Accommodations/Expenses): Astellas, BeiGene, Elevation Oncology, PRIME
Jaffer A. Ajani, MD 
Prof., Dept. of Gastrointestinal Medical Oncology 
Division of Cancer Medicine 
The University of Texas MD Anderson Cancer Center 
Houston, TX 
Dr. Ajani has no relevant relationships reported
Reviewers/Content Planners/Authors:
- Tim Person has nothing to disclose.
- Jocelyn Timko has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Diferentiate between current and emerging anti-PD-1 agents in combination regimens for ESCC
- Evaluate practice-changing data on the use of first-line ICI and chemotherapy regimens in patients with metastatic ESCC
- Implement evidence-based strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes
- Apply pivotal data and guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and gastroenterologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with metastatic esophageal squamous cell carcinoma.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/0.075 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-150-H01-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until 3/30/2026. PAs should claim only the credit commensurate with the extent of their participation in the activity,
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from BeiGene USA, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/20/2024
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.